ArticleFrontiers in cell and developmental biology2025
Cnicin: a promising drug for promoting nerve repair.
Article in Frontiers in cell and developmental biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Stem Cell-Derived Exosomes: A Cell-Free Frontier in Peripheral Nerve Regeneration.Stem cell reviews and reports · 2026Article
- Microtubules in Spinal Cord Injury: From Cytoskeletal Dysregulation to Therapeutic Regeneration.Journal of neurochemistry · 2026Review
- Phase-Specific Evaluation of Sciatic Nerve Regeneration in Preclinical Studies: A Review of Functional Assessment, Emerging Therapies, and Translational Value.International journal of molecular sciences · 2025Review
- Cnicin Attenuates Aluminium Chloride-Induced Neurodegeneration Through Antioxidant and Anti-Inflammatory Mechanisms.Dose-response : a publication of International Hormesis SocietyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Traumatic peripheral nerve injuries frequently result in irreversible functional deficits. While neurons possess an intrinsic capacity for axonal regeneration, the temporal constraints and the slow pace of neurite outgrowth often impede the complete restoration of sensory and motor capabilities. This impairment, often culminating in chronic disability, represents a significant clinical challenge, as there are currently no approved pharmacological interventions available to accelerate axon regeneration and improve functional recovery. This perspective focuses on recent scientific advancements that have identified sesquiterpene lactones, a family of naturally derived plant metabolites, as potential therapeutic candidates for treating peripheral nerve trauma. Preclinical investigations employing parthenolide and cnicin have revealed that these compounds can substantially augment axonal extension and functional recovery in diverse
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.